Post-COVID-19 functional status six-months after hospitalization

Taboada, Manuel; Cariñena, Agustín; Moreno, E.; Rodríguez, Núria; Domínguez, M. J.; Casal, Ana; Riveiro, Vanessa; Diaz-Vieito, María; Valdés, Luís; Álvarez, Julián; Seoane-Pillado, Teresa

doi:10.1016/j.jinf.2020.12.022

Cited by 124 publications

(115 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The rest of the selected studies range from 37 days to 4 months. It is worthwhile pointing out that within these three studies, 63% of patients from one study reported fatigue (Huang et al [45]) and 47.5% of patients from another reported decreased functional status (Taboada et al [47]). In other words, a significant number of patients continue to suffer from long COVID symptoms after 6 months, seemingly at levels comparable to data from studies involving shorter time courses.…”

Section: Discussionmentioning

confidence: 95%

See 1 more Smart Citation

Long COVID and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)—A Systemic Review and Comparison of Clinical Presentation and Symptomatology

2021

View full text Add to dashboard Cite

Background and Objectives: Long COVID defines a series of chronic symptoms that patients may experience after resolution of acute COVID-19. Early reports from studies with patients with long COVID suggests a constellation of symptoms with similarities to another chronic medical illness—myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). A review study comparing and contrasting ME/CFS with reported symptoms of long COVID may yield mutualistic insight into the characterization and management of both conditions. Materials and Methods: A systemic literature search was conducted in MEDLINE and PsycInfo through to 31 January 2021 for studies related to long COVID symptomatology. The literature search was conducted in accordance with PRISMA methodology. Results: Twenty-one studies were included in the qualitative analysis. Long COVID symptoms reported by the included studies were compared to a list of ME/CFS symptoms compiled from multiple case definitions. Twenty-five out of 29 known ME/CFS symptoms were reported by at least one selected long COVID study. Conclusions: Early studies into long COVID symptomatology suggest many overlaps with clinical presentation of ME/CFS. The need for monitoring and treatment for patients post-COVID is evident. Advancements and standardization of long COVID research methodologies would improve the quality of future research, and may allow further investigations into the similarities and differences between long COVID and ME/CFS.

show abstract

Section: Discussionmentioning

confidence: 95%

“…The diagnosis of ME/CFS requires that the symptoms have been present for at least 6 months. Only three of the selected studies involved the assessment of patients more than 6 months after the onset of their COVID symptoms (Huang et al [45], Taboada et al [47], Ludvigsson [57]). The rest of the selected studies range from 37 days to 4 months.…”

Section: Discussionmentioning

confidence: 99%

Long COVID and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)—A Systemic Review and Comparison of Clinical Presentation and Symptomatology

2021

View full text Add to dashboard Cite

show abstract

“…We also summarized all the current data regarding persistent symptoms after acute COVID-19 (see Table 3). According to the available evidence [3][4][5][6][7][8][18][19][20][21][22][23][24][25][26], the most frequent symptoms during follow-up are dyspnea and fatigue. Six studies evaluated pulmonary function, detecting a decrease in DL CO with a normal FEV1/FVC in the global post-COVID-19 population at short-term follow-up [5][6][7][8]24].…”

Section: Summary Of Published Evidencementioning

confidence: 99%

“…The high rate of post-COVID-19 symptomatic patients is in agreement with alternative coronavirus outbreaks. Although several studies have explored the symptom burden [3][4][5][6][7][8][18][19][20][21][22][23][24][25][26], similarly reporting a substantial proportion of patients with persistent dyspnea and fatigue, limited information exists regarding exercise capacity [5][6][7][8]24]. Two prior studies have reported a decreased 6-MWT distance among survivors [5,21,24].…”

Section: Rationale For Post-covid-19 Symptom Persistencementioning

confidence: 99%

Exercise Ventilatory Inefficiency in Post-COVID-19 Syndrome: Insights from a Prospective Evaluation

Alonso

Ybarra-Falcón

García-Gómez

et al. 2021

JCM

View full text Add to dashboard Cite

Introduction: Coronavirus disease 2019 (COVID-19) is a systemic disease characterized by a disproportionate inflammatory response in the acute phase. This study sought to identify clinical sequelae and their potential mechanism. Methods: We conducted a prospective single-center study (NCT04689490) of previously hospitalized COVID-19 patients with and without dyspnea during mid-term follow-up. An outpatient group was also evaluated. They underwent serial testing with a cardiopulmonary exercise test (CPET), transthoracic echocardiogram, pulmonary lung test, six-minute walking test, serum biomarker analysis, and quality of life questionaries. Results: Patients with dyspnea (n = 41, 58.6%), compared with asymptomatic patients (n = 29, 41.4%), had a higher proportion of females (73.2 vs. 51.7%; p = 0.065) with comparable age and prevalence of cardiovascular risk factors. There were no significant differences in the transthoracic echocardiogram and pulmonary function test. Patients who complained of persistent dyspnea had a significant decline in predicted peak VO2 consumption (77.8 (64–92.5) vs. 99 (88–105); p < 0.00; p < 0.001), total distance in the six-minute walking test (535 (467–600) vs. 611 (550–650) meters; p = 0.001), and quality of life (KCCQ-23 60.1 ± 18.6 vs. 82.8 ± 11.3; p < 0.001). Additionally, abnormalities in CPET were suggestive of an impaired ventilatory efficiency (VE/VCO2 slope 32 (28.1–37.4) vs. 29.4 (26.9–31.4); p = 0.022) and high PETCO2 (34.5 (32–39) vs. 38 (36–40); p = 0.025). Interpretation: In this study, >50% of COVID-19 survivors present a symptomatic functional impairment irrespective of age or prior hospitalization. Our findings suggest a potential ventilation/perfusion mismatch or hyperventilation syndrome.

show abstract

“…The long-COVID-19 is affecting a growing number of COVID-19 patients and has become a major cause of increasing burden on healthcare system. Long-term follow-up studies on the prolonged symptoms have been published from many countries with longest follow up of around 6-9 months till date [2,3,4,5], but the adequate knowledge is lacking on persistence for higher duration and on specific symptoms, duration for recovery and association with any comorbidity, severity of acute phase of COVID-19 illness and age of the patient, particularly for the patients in India.…”

Section: Introductionmentioning

confidence: 99%

Long Term Health Consequences of COVID-19 in Hospitalized Patients from North India: A follow up study of upto 12 months

Budhiraja

Aggarwal

Wig

et al. 2021

Preprint

View full text Add to dashboard Cite

Purpose: Long COVID syndrome is now a real and pressing public health concern. We cannot reliably predict who will recover quickly or suffer with mild debilitating long COVID 19 symptoms or battle life threatening complications. In order to address some of these questions, we studied the presence of symptoms and various correlates in COVID 19 patients who were discharged from hospital, 3 months and up to 12 months after acute COVID 19 illness. Methods: This is an observational follow up study of RT PCR confirmed COVID 19 patients admitted at 3 hospitals in north India between April August 2020. Patients were interviewed telephonically using a questionnaire regarding the post COVID symptoms. The first tele calling was done in the month of September 2020, which corresponded to 4 to 16 weeks after disease onset. All those who reported presence of long COVID symptoms, were followed up with a second call, in the month of March 2021, corresponding to around 9 to 12 months after the onset of disease. Results: Of 990 patients who responded to the first call, 615 (62.2%) had mild illness, 227 (22.9%) had moderate and 148 (15.0%) had severe COVID 19 illness at the time of admission. Nearly 40% (399) of these 990 patients reported at least one symptom at that time. Of these 399 long COVID patients, 311 (almost 78%) responded to the second follow up. Nearly 8% reported ongoing symptomatic COVID, lasting 1 to 3 months and 32% patients having post COVID phase with symptoms lasting 3 to 12 months. Nearly 11% patients continued to have at least one symptom even at the time of the second interview (9 to 12 months after the disease onset). Overall, we observed Long COVID in almost 40% of our study group. Incidence of the symptoms in both the follow ups remained almost same across age groups, gender, severity of illness at admission and presence of comorbidity, with no significant association with any of them. Most common symptoms experienced in long COVID phase in our cohort were fatigue, myalgia, neuro psychiatric symptoms like depression, anxiety, brain fog and sleep disorder, and breathlessness. Fatigue was found to be significantly more often reported in the elderly population and in those patients who had a severe COVID 19 illness at the time of admission. Persistence of breathlessness was also reported significantly more often in those who had severe disease at the onset. The overall median duration of long COVID symptoms was 16.9 weeks with inter quartile range of 12.4 to 35.6 weeks. The duration of symptom resolution was not associated with age, gender or comorbidity but was significantly associated with severity of illness at the time of admission (P=0.006). Conclusions: Long COVID is now being recognized as a new disease entity, which includes a constellation of symptoms. Long COVID was in almost 40% of our study group with no correlation to age, gender, comorbidities or to the disease severity. The duration of symptom resolution was significantly associated with severity of illness at the time of admission (P = 0.006). In our study, all patients reported minor symptoms such as fatigue, myalgia, neuro psychiatric symptoms like depression, anxiety, brain fog and sleep disorder and persistence of breathlessness. Severe organ damage was not reported by our subjects. This might be the longest post COVID follow up study on a sample of nearly 1000 cases from India.

show abstract

Post-COVID-19 functional status six-months after hospitalization

Cited by 124 publications

References 10 publications

Long COVID and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)—A Systemic Review and Comparison of Clinical Presentation and Symptomatology

Long COVID and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)—A Systemic Review and Comparison of Clinical Presentation and Symptomatology

Exercise Ventilatory Inefficiency in Post-COVID-19 Syndrome: Insights from a Prospective Evaluation

Long Term Health Consequences of COVID-19 in Hospitalized Patients from North India: A follow up study of upto 12 months

Contact Info

Product

Resources

About